Dermira Company Profile (NASDAQ:DERM)

Analyst Ratings

Consensus Ratings for Dermira (NASDAQ:DERM) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $43.17 (25.59% upside)

Analysts' Ratings History for Dermira (NASDAQ:DERM)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Needham & Company LLCReiterated RatingBuy$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Leerink SwannReiterated RatingBuy$46.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Citigroup Inc.Lower Price TargetBuy$42.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2015Cowen and CompanyInitiated CoverageOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015GuggenheimBoost Price TargetBuy$22.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Dermira (NASDAQ:DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q4($0.95)($1.04)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.77)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015Q4($0.59)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dermira (NASDAQ:DERM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($1.00)($1.00)($1.00)
Q2 20161($0.96)($0.96)($0.96)
Q3 20161($0.72)($0.72)($0.72)
Q4 20161($0.97)($0.97)($0.97)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dermira (NASDAQ:DERM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dermira (NASDAQ:DERM)
DateHeadline
07/28/16 09:30 AMGlobal Systemic Psoriasis Therapeutics Market to Grow at a CAGR of 9.41% During the Period 2016 - 2020; Finds New Report
07/27/16 09:15 PMCan Shares Of Dermira, Inc. (NASDAQ:DERM) Hit $47? - Investor Newswire
07/21/16 07:03 AMIs $47 Price Target Attainable For Dermira, Inc. (NASDAQ:DERM)? - Investor Newswire
07/19/16 03:40 PMStock in Positive Territory for the Quarter: Dermira, Inc. (NASDAQ:DERM) - Engelwood Daily
07/16/16 04:01 AMShares Experiencing a Downtrend: Dermira, Inc. (NASDAQ:DERM) - TGP
07/15/16 07:08 AMDermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : July 15, 2016 -
07/13/16 08:53 PMAfter Today's Huge Decline, Is Dermira Inc's Near-Term Analysis Negative? - Consumer Eagle
07/13/16 08:53 PMStrong Sell Calls For Dermira, Inc. (NASDAQ:DERM) At 0 - Investor Newswire
07/13/16 03:43 PMDermira (NASDAQ:DERM) Sentiment Change Report - Press Telegraph
07/13/16 03:43 PMWere Analysts Bearish Dermira Inc (NASDAQ:DERM) This Week? - Press Telegraph
07/13/16 03:43 PMStock Performance Rundown on: Dermira, Inc. (NASDAQ:DERM) - Press Telegraph
07/13/16 03:43 PMBroker Outlook For Dermira, Inc. (NASDAQ:DERM) - Fiscal Standard
07/07/16 08:47 PMOption Market: Dermira Inc. Risk Hits An Elevated Level - CML News
07/06/16 09:25 PMInsider Trading Activity - Dermira, Inc. (NASDAQ:DERM) - Finance Daily
07/06/16 09:25 PMDermira, Inc. (NASDAQ:DERM) Expected to Reach Highs Of $47 - Investor Newswire
07/05/16 03:32 PMShare Performance Recap for: Dermira, Inc. (NASDAQ:DERM) - Press Telegraph
07/05/16 08:21 AMThis Weeks Broker Price Targets For Dermira, Inc. (NASDAQ:DERM) - Fiscal Standard
06/30/16 08:57 PMDermira Inc Can't Burn Your Short Portfolio. Has Another Weak Session - Press Telegraph
06/29/16 08:36 PMStrong Sell Calls Recommendations For Dermira, Inc. (NASDAQ:DERM) At 0 - Investor Newswire
06/29/16 03:34 PMWhy Need to Watch: Dermira, Inc. (NASDAQ:DERM), Bristol-Myers Squibb Company (NYSE:BMY), Rite Aid ... - KC Register
06/28/16 07:33 AMDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : June 28, 2016 -
06/27/16 03:34 PMNext Weeks Broker Price Targets For Dermira, Inc. (NASDAQ:DERM) - Fiscal Standard
06/27/16 03:34 PMHow Many Dermira Inc (NASDAQ:DERM)'s Analysts Are Bearish? - Press Telegraph
06/24/16 10:19 AMForm 4 Dermira, Inc. For: Jun 21 Filed by: CRAVES FRED B - StreetInsider.com
06/23/16 02:30 PMLooking At Post-Earnings Stock Movement: Dermira, Inc. (NASDAQ:DERM) - iStreetWire
06/23/16 02:30 PMStrong Buy Calls Count For Dermira, Inc. (NASDAQ:DERM) At 2 - Investor Newswire
06/22/16 08:49 PMDERMIRA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/22/16 03:45 PMDermira, Inc. (NASDAQ:DERM) Current Analyst Ratings - Fiscal Standard
06/22/16 03:10 PMDERMIRA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 03:30 PMDermira, Inc. (NASDAQ:DERM) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 07:56 AMTrend Of Rating Given To Dermira, Inc. (NASDAQ:DERM) - Investor Newswire
06/13/16 03:05 PMDermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - [GlobeNewswire] - MENLO PARK, Calif., June 13, 2016-- Dermira, Inc., a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients ...
06/09/16 10:52 AMTrending Stock Analysis: Dermira, Inc. (NASDAQ:DERM) - News Oracle
06/09/16 10:52 AMAnalyst Rating Fluctuations to Observe: UnitedHealth Group Incorporated (NYSE:UNH) , Dermira, Inc. (NASDAQ:DERM) - Street Updates
06/08/16 08:22 PMPre-Market Investor's Watch List: Dermira Inc.(NASDAQ:DERM), AK Steel Holding Corporation(NYSE:AKS) - iStreetWire
06/08/16 08:22 PMDERMIRA INC. (NASDAQ:DERM) Financial Condition Compared to S&P 500 - CML News
06/08/16 03:09 PMDERMIRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and -
06/08/16 06:08 AMDermira Prices $126 Million Public Offering of Common Stock - [at noodls] - MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies ...
06/08/16 06:01 AM7:01 am Dermira prices 4.5 mln common stock offering at $28.00/share -
06/07/16 09:12 PMMaruho Co., Ltd. - Strategic SWOT Analysis Review - New Market Report
06/07/16 03:28 PMDermira Announces Proposed Public Offering of Common Stock - [at noodls] - MENLO PARK, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies ...
06/06/16 04:40 AMDrug for excessive armpit sweating succeeds in key studies
06/03/16 10:21 AMMedivation Inc (NASDAQ:MDVN) & Dermira Inc (NASDAQ:DERM) Healthcare Stocks in Focus - Wall Street 24
06/02/16 12:50 PMDermira (DERM) Stock Slumps Despite Favorable Trial Results -
06/02/16 12:17 PMMaker of sweaty armpit treatment sees shares slide -
06/02/16 09:40 AMDermira Inc (NASDAQ:DERM): A Slow Burner, But One To Watch - Market Exclusive - Market ExclusiveDermira Inc (NASDAQ:DERM): A Slow Burner, But One To WatchMarket ExclusiveDermira Inc (NASDAQ:DERM) just reported topline from its pivotal DRM04 trial. The trial investigated the efficacy of a condition called hyperhidrosis – a condition that affects more than 4 million individuals in the US. It's essentially an over ...Analysts At Needham Reiterated Dermira Inc (NASDAQ:DERM) As BuyRisers & FallersDermira Inc. (DERM) Is Climbing On Phase 3 Study ResultsRTT News3 Stocks to Watch on Thursday: Ciena Corporation (CIEN), Dermira Inc (DERM) and Joy Global Inc. (JOY)Investorplace.comLet Me Know About This -Market Digest -The Wall Street Transcriptall 18 news articles »
06/01/16 03:45 PMDermira Inc.: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in ... - The Wall Street Transcript - Reuters UKDermira Inc.: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in ...The Wall Street TranscriptMENLO PARK, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with ...Dermira's drug for excessive armpit sweating succeeds in key studiesChannel News Asiaall 2 news articles »
06/01/16 03:25 PMDermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis - [at noodls] - MENLO PARK, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies ...
06/01/16 03:15 PMDermira's drug for excessive armpit sweating succeeds in key studies - [Reuters] - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the embarrassing, ...
05/31/16 03:39 PMDermira, Inc. (NASDAQ:DERM) Stock Update & Estimates - Stock Tick Tock - Dermira, Inc. (NASDAQ:DERM) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Dermira, Inc. (NASDAQ:DERM) to post earnings of $-0.96 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »

Social

About Dermira

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company's portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DERM
  • CUSIP:
Key Metrics:
  • Previous Close: $34.37
  • 50 Day Moving Average: $30.19
  • 200 Day Moving Average: $26.51
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.03B
  • Beta: 0.75
  • Current Year EPS Consensus Estimate: $-3.63 EPS
  • Next Year EPS Consensus Estimate: $-3.21 EPS
Additional Links:
Dermira (NASDAQ:DERM) Chart for Thursday, July, 28, 2016